2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4892
    Amyloid β-Protein (4-42)
    Amyloid β-Protein (4-42) is aAβ Fragment.
    Amyloid β-Protein (4-42)
  • HY-167898
    MeS-IMPY
    MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (Ki=7.93 and 8.95 nM, respectively). [11C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET).
    MeS-IMPY
  • HY-157440
    AChE/Aβ-IN-3
    		Inhibitor
    AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease.
    AChE/Aβ-IN-3
  • HY-161658
    N-Caffeoyldopamine
    		Inhibitor
    N-Caffeoyldopamine (Compound 6i) is an amyloid-beta aggregation inhibitor. N-Caffeoyldopamine can inhibit Aβ aggregation to form nano-rod-like structures, thereby preventing β-sheet formation. N-Caffeoyldopamine can be used for Alzheimer's disease research.
    N-Caffeoyldopamine
  • HY-131660
    MAO-B-IN-54
    		Inhibitor
    MAO-B-IN-54 is a selective, reversible and competitiv monoamine oxidase B (MAOB) inhibitor with a human IC50 of 0.052 μM and a Ki of 0.028 μM. MAO-B-IN-54 shows weak activity MAOA. MAO-B-IN-54 occupies both the entrance and substrate cavity of MAOB, forming hydrophobic and hydrogen bonding interactions. MAO-B-IN-54 inhibits Aβ aggregation and ROS production. MAO-B-IN-54 can be used for the research of Alzheimer’s disease.
    MAO-B-IN-54
  • HY-W748591R
    Cannflavin A (Standard)
    		Inhibitor
    Cannflavin A (Standard) is the analytical standard of Cannflavin A. This product is intended for research and analytical applications. Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC50 = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line.
    Cannflavin A (Standard)
  • HY-125405
    AZ3971
    		Inhibitor
    AZ3971 is an orally active, blood-brain barrier permeable BACE1 inhibitor that does not affect the activity of γ-secretase. AZ3971 reduces the production of Aβ. AZ3971 can be used for the research of Alzheimer's disease.
    AZ3971
  • HY-P1867
    β-Amyloid (1-34)
    β-Amyloid (1-34) is a β-Amyloid peptide consists of 34 amino acid.
    β-Amyloid (1-34)
  • HY-114613
    D-Trp-Aib
    		Inhibitor
    D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a Kd of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease.
    D-Trp-Aib
  • HY-177854
    Aβ aggregation-IN-4
    		Inhibitor
    Aβ aggregation-IN-4 can alleviate the neurotoxicity of amyloid-β protein (Aβ) and significantly reduce the level of oligomeric complexes of Aβ (Aβ-OCs). Aβ aggregation-IN-4 does not decrease the level of amyloid-β protein (Aβ). Aβ aggregation-IN-4 attenuates Aβ oligomerization and prevents oligomer-induced death of primary cortical neurons. Aβ aggregation-IN-4 can be used for the study of Alzheimer’s disease (AD).
    Aβ aggregation-IN-4
  • HY-149582
    Aβ-IN-7
    		Inhibitor
    Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM.
    Aβ-IN-7
  • HY-P0265AS
    β-Amyloid-15N (1-40) TFA
    β-Amyloid-15N (1-40) (TFA) is the 15N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.
    β-Amyloid-<sup>15</sup>N (1-40) TFA
  • HY-P10613
    RERMS
    RERMS are bioactive peptides produced from the active regions of amyloid-β and A4 protein precursors that promote fibroblast growth and can be used in the study of neurodegenerative diseases.
    RERMS
  • HY-P3860
    Biotinyl-Amyloid β-Protein (1-42) ammonium
    Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain.
    Biotinyl-Amyloid β-Protein (1-42) ammonium
  • HY-172782
    BuChE-IN-20
    		Inhibitor
    BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC50 = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease.
    BuChE-IN-20
  • HY-P1060A
    LPYFD-NH2 TFA
    LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease.
    LPYFD-NH2 TFA
  • HY-120804
    PH-46A
    		Inhibitor
    PH-46A is an indane dimer with anti-inflammatory activity. PH-46A can reduced histological damage and serum amyloid A (SAA) levels in colitis mice.
    PH-46A
  • HY-137315S
    TML-6-d3
    TML-6-d3 is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-
    TML-6-d<sub>3</sub>
  • HY-153431
    TRV-1387
    		Inhibitor
    TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β.
    TRV-1387
  • HY-119492
    Phenchlobenpyrrone
    		Inhibitor
    Phenchlobenpyrrone is a highly selective neuronal calcium antagonist that crosses the blood-brain barrier. Phenchlobenpyrrone mildly inhibits AChE activity. Phenchlobenpyrrone inhibits Aβ aggregation and promotes the clearance of Aβ oligomers. Phenchlobenpyrrone reduces abnormal phosphorylation of Tau protein. Phenchlobenpyrrone may be used in research on Alzheimer's disease.
    Phenchlobenpyrrone
Cat. No. Product Name / Synonyms Application Reactivity